Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| GEND_GBV |
15-19, Female, Physical and/or Emotional Violence |
2018 |
180 |
| GEND_GBV |
15-19, Female, Physical and/or Emotional Violence |
2018 |
3,766 |
| GEND_GBV |
15-19, Female, Sexual Violence (Post-Rape Care) |
2018 |
1,003 |
| GEND_GBV |
15-19, Male, Physical and/or Emotional Violence |
2018 |
192 |
| GEND_GBV |
15-19, Male, Sexual Violence (Post-Rape Care) |
2018 |
79 |
| GEND_GBV |
20-24, Female, Physical and/or Emotional Violence |
2018 |
270 |
| GEND_GBV |
20-24, Female, Physical and/or Emotional Violence |
2018 |
4,186 |
| GEND_GBV |
20-24, Female, Sexual Violence (Post-Rape Care) |
2018 |
1,207 |
| GEND_GBV |
20-24, Male, Physical and/or Emotional Violence |
2018 |
349 |
| GEND_GBV |
20-24, Male, Sexual Violence (Post-Rape Care) |
2018 |
129 |
| GEND_GBV |
25-49, Female, Physical and/or Emotional Violence |
2018 |
1,868 |
| GEND_GBV |
25-49, Female, Sexual Violence (Post-Rape Care) |
2018 |
749 |
| GEND_GBV |
25-49, Male, Physical and/or Emotional Violence |
2018 |
594 |
| GEND_GBV |
25-49, Male, Sexual Violence (Post-Rape Care) |
2018 |
222 |
| GEND_GBV |
50+, Female, Physical and/or Emotional Violence |
2018 |
69 |
| GEND_GBV |
50+, Female, Sexual Violence (Post-Rape Care) |
2018 |
27 |
| GEND_GBV |
50+, Male, Physical and/or Emotional Violence |
2018 |
20 |
| GEND_GBV |
50+, Male, Sexual Violence (Post-Rape Care) |
2018 |
7 |
| GEND_GBV |
By PEP service provision (related to sexual violence services provided) |
2018 |
685 |
| GEND_GBV |
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) |
2018 |
907 |
| GEND_GBV |
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) |
2018 |
11,046 |
| GEND_GBV |
By type of service: Sexual Violence (Post-Rape Care) |
2018 |
544 |
| GEND_GBV |
By type of service: Sexual Violence (Post-Rape Care) |
2018 |
3,425 |
| GEND_GBV |
Number of people receiving post-GBV care |
2018 |
1,451 |
| GEND_GBV |
Number of people receiving post-GBV care |
2018 |
14,472 |
| HTS_TST |
By Key Population: FSW, Negative |
2018 |
4,112 |
| HTS_TST |
By Key Population: MSM, Negative |
2018 |
820 |
| HTS_TST |
By Key Population: PWID, Negative |
2018 |
572 |
| HTS_TST |
By Key Population: TG, Negative |
2018 |
1,288 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2018 |
164,119 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2018 |
4,352 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 1-9, Negative |
2018 |
3,239 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative |
2018 |
3,209 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative |
2018 |
1,375 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative |
2018 |
7,958 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative |
2018 |
5,029 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative |
2018 |
23,701 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative |
2018 |
18,083 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative |
2018 |
30,273 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative |
2018 |
31,130 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 50+, Female, Negative |
2018 |
1,045 |
| HTS_TST |
Service Delivery Point (Community) Homebased testing: 50+, Male, Negative |
2018 |
1,253 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 1-9, Negative |
2018 |
84 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative |
2018 |
54 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative |
2018 |
30 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative |
2018 |
134 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative |
2018 |
89 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative |
2018 |
483 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative |
2018 |
371 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative |
2018 |
657 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative |
2018 |
738 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative |
2018 |
21 |
| HTS_TST |
Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative |
2018 |
30 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 1-9, Negative |
2018 |
1,247 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 10-14, Female, Negative |
2018 |
1,044 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 10-14, Male, Negative |
2018 |
570 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 15-19, Female, Negative |
2018 |
1,659 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 15-19, Male, Negative |
2018 |
964 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 20-24, Female, Negative |
2018 |
5,597 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 20-24, Male, Negative |
2018 |
4,569 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 25-49, Female, Negative |
2018 |
8,322 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 25-49, Male, Negative |
2018 |
8,701 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 50+, Female, Negative |
2018 |
295 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 50+, Male, Negative |
2018 |
365 |
| HTS_TST |
Sum of Test Result disaggregates |
2018 |
1,841 |
| HTS_TST_POS |
By Key Population: FSW, Positive |
2018 |
379 |
| HTS_TST_POS |
By Key Population: MSM, Positive |
2018 |
40 |
| HTS_TST_POS |
By Key Population: PWID, Positive |
2018 |
4 |
| HTS_TST_POS |
By Key Population: TG, Positive |
2018 |
10 |
| HTS_TST_POS |
By Test Result: Positive |
2018 |
1,841 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 1-9, Positive |
2018 |
22 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive |
2018 |
16 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive |
2018 |
14 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive |
2018 |
69 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive |
2018 |
67 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive |
2018 |
251 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive |
2018 |
212 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive |
2018 |
354 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive |
2018 |
347 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 50+, Female, Positive |
2018 |
14 |
| HTS_TST_POS |
Service Delivery Point (Community) Homebased testing: 50+, Male, Positive |
2018 |
16 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 1-9, Positive |
2018 |
2 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive |
2018 |
2 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive |
2018 |
2 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive |
2018 |
4 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive |
2018 |
2 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive |
2018 |
12 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive |
2018 |
10 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive |
2018 |
10 |
| HTS_TST_POS |
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive |
2018 |
12 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 1-9, Positive |
2018 |
5 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 10-14, Female, Positive |
2018 |
4 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 10-14, Male, Positive |
2018 |
3 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 15-19, Female, Positive |
2018 |
17 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 15-19, Male, Positive |
2018 |
17 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 20-24, Female, Positive |
2018 |
67 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 20-24, Male, Positive |
2018 |
54 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 25-49, Female, Positive |
2018 |
93 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 25-49, Male, Positive |
2018 |
96 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 50+, Female, Positive |
2018 |
2 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 50+, Male, Positive |
2018 |
3 |
| KP_PREV |
By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2018 |
7,693 |
| KP_PREV |
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2018 |
476 |
| KP_PREV |
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2018 |
111 |
| KP_PREV |
By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2018 |
1,269 |
| KP_PREV |
By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2018 |
24 |
| KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2018 |
9,573 |
| OVC_SERV |
Age/Sex: 15-17 Female |
2018 |
8,422 |
| OVC_SERV |
By: Age/sex: 18-24 Female |
2018 |
4,149 |
| OVC_SERV |
Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS |
2018 |
12,571 |
| OVC_SERV |
Program Completion: Active |
2018 |
12,571 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17 |
2018 |
472 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24 |
2018 |
2,043 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 |
2018 |
2,526 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24 |
2018 |
1,245 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17 |
2018 |
5,029 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24 |
2018 |
7,542 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 |
2018 |
565 |
| OVC_SERV |
Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24 |
2018 |
1,321 |
| OVC_SERV |
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17 |
2018 |
3,657 |
| OVC_SERV |
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24 |
2018 |
5,486 |
| OVC_SERV |
Sum of Age/Sex disaggregates |
2018 |
8,422 |
| PP_PREV |
Age/sex: 15-19 Female |
2018 |
13,120 |
| PP_PREV |
Age/sex: 15-19 Male |
2018 |
489 |
| PP_PREV |
Age/sex: 20-24 Female |
2018 |
12,710 |
| PP_PREV |
Age/sex: 20-24 Male |
2018 |
1,558 |
| PP_PREV |
Age/sex: 25-49 Female |
2018 |
4,441 |
| PP_PREV |
Age/sex: 25-49 Male |
2018 |
7,102 |
| PP_PREV |
Age/sex: 50+ Female |
2018 |
425 |
| PP_PREV |
Age/sex: 50+ Male |
2018 |
645 |
| PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2018 |
40,490 |
| PP_PREV |
Sum of Age/Sex disaggregates |
2018 |
40,490 |
| PrEP_NEW |
Female 15-19 |
2018 |
308 |
| PrEP_NEW |
Female 20-24 |
2018 |
285 |
| PrEP_NEW |
Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection |
2018 |
593 |
| TB_ART |
Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2018 |
1 |
| TB_ART |
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2018 |
1 |
| TB_ART |
Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2018 |
1 |
| TB_ART |
Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2018 |
3 |
| TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period |
2018 |
6 |
| TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2018 |
6 |
| TB_ART_den |
Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) |
2018 |
1 |
| TB_ART_den |
Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) |
2018 |
1 |
| TB_ART_den |
Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) |
2018 |
1 |
| TB_ART_den |
Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) |
2018 |
3 |
| TB_PREV |
By Age/Sex (Numerator): <15, Female |
2018 |
230 |
| TB_PREV |
By Age/Sex (Numerator): <15, Male |
2018 |
178 |
| TB_PREV |
By Age/Sex (Numerator): 15+, Female |
2018 |
342 |
| TB_PREV |
By Age/Sex (Numerator): 15+, Male |
2018 |
271 |
| TB_PREV |
By Therapy type (Numerator): 6-12 Month IPT |
2018 |
818 |
| TB_PREV |
By Therapy type (Numerator): Continuous IPT |
2018 |
203 |
| TB_PREV |
The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period |
2018 |
1,021 |
| TB_PREV |
The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) |
2018 |
1,135 |
| TB_PREV_den |
By Age/Sex (Denominator): <15, Female |
2018 |
331 |
| TB_PREV_den |
By Age/Sex (Denominator): <15, Male |
2018 |
214 |
| TB_PREV_den |
By Age/Sex (Denominator): 15+, Female |
2018 |
296 |
| TB_PREV_den |
By Age/Sex (Denominator): 15+, Male |
2018 |
294 |
| TB_PREV_den |
By Therapy type (Denominator): 6-12 Month IPT |
2018 |
909 |
| TB_PREV_den |
By Therapy type (Denominator): Continuous IPT |
2018 |
226 |
| TB_STAT |
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2018 |
1 |
| TB_STAT |
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2018 |
1 |
| TB_STAT |
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2018 |
1 |
| TB_STAT |
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2018 |
3 |
| TB_STAT |
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period |
2018 |
6 |
| TB_STAT |
Total number of registered new and relapsed TB cases, during the reporting period |
2018 |
6 |
| TB_STAT_den |
Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2018 |
1 |
| TB_STAT_den |
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2018 |
1 |
| TB_STAT_den |
Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2018 |
1 |
| TB_STAT_den |
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2018 |
3 |
| TX_CURR |
Aggregated Age/Sex: <15 Female |
2018 |
110 |
| TX_CURR |
Aggregated Age/Sex: <15 Male |
2018 |
83 |
| TX_CURR |
Aggregated Age/Sex: 15+ Female |
2018 |
2,222 |
| TX_CURR |
Aggregated Age/Sex: 15+ Male |
2018 |
1,676 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2018 |
4,091 |
| TX_CURR |
Sum of Aggregated Age/Sex <15 |
2018 |
193 |
| TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2018 |
3,898 |
| TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2018 |
4,091 |
| TX_NEW |
Aggregated Grouping by Age/Sex: <15 Female |
2018 |
16 |
| TX_NEW |
Aggregated Grouping by Age/Sex: <15 Male |
2018 |
12 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2018 |
632 |
| TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2018 |
475 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2018 |
1,135 |
| TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2018 |
1,135 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2018 |
5,124 |
| TX_PVLS |
Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months |
2018 |
4,595 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine |
2018 |
86 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted |
2018 |
6 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine |
2018 |
58 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted |
2018 |
5 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2018 |
2,448 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted |
2018 |
186 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2018 |
1,678 |
| TX_PVLS |
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted |
2018 |
128 |
| TX_PVLS |
Numerator: Indication: Routine |
2018 |
4,270 |
| TX_PVLS |
Numerator: Indication: Targeted |
2018 |
325 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Female Routine |
2018 |
102 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted |
2018 |
8 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Male Routine |
2018 |
78 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted |
2018 |
6 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2018 |
2,613 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted |
2018 |
197 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2018 |
1,972 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted |
2018 |
148 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2018 |
4,765 |
| TX_PVLS_den |
Denominator: Indication: Targeted |
2018 |
359 |
| TX_RET |
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2018 |
27 |
| TX_RET |
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2018 |
19 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2018 |
617 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2018 |
415 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2018 |
1,078 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2018 |
1,129 |
| TX_RET_den |
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2018 |
18 |
| TX_RET_den |
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2018 |
13 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2018 |
632 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2018 |
466 |
| TX_TB |
Number of ART patients who were screened for TB at least once during the reporting period |
2018 |
2 |
| TX_TB |
Number of ART patients who were started on TB treatment during the reporting period |
2018 |
2 |
| TX_TB |
Numerator: By Aggregated Age/Sex: 15+, Female |
2018 |
1 |
| TX_TB |
Numerator: By Aggregated Age/Sex: 15+, Male |
2018 |
1 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex:15+, Female |
2018 |
1 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex:15+, Male |
2018 |
1 |
| TX_TB_den |
Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay |
2018 |
2 |
| TX_TB_den |
Denominator: By Screen Result: Positive |
2018 |
2 |
| TX_TB_den |
Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease |
2018 |
2 |
